Current status of cediranib: The rapid development of a novel anti-angiogenic therapy

Future Oncology

Volumn 5, Issue 4, 2009, Pages 421-432

  Lindsay, Colin R ^a,b   MacPherson, Iain R J ^a   Cassidy, Jim ^a,b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Angiogenesis; AZD2171; Cancer; Cediranib; Recentin

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; GEFITINIB; GEMCITABINE; IMATINIB; OXALIPLATIN; PACLITAXEL; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TAMOXIFEN; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; 4 ((4 FLUORO 2 METHYL 1H INDOL 5 YL)OXY) 6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINAZOLINE; 4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-(3-(PYRROLIDIN-1-YL)PROPOXY)QUINAZOLINE; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A;

ABDOMINAL PAIN; ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CENTRAL NERVOUS SYSTEM ISCHEMIA; CLINICAL STUDY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK TUMOR; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOUTH PAIN; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONHUMAN; OROPHARYNGEAL IRRITATION; OVARY CANCER; PHARYNX DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; QT PROLONGATION; RECOMMENDED DRUG DOSE; RECTUM CANCER; SIDE EFFECT; SOLID TUMOR; SYSTOLIC DYSFUNCTION; THROMBOCYTOPENIA; THYROID CANCER; TUMOR XENOGRAFT; URINARY TRACT CANCER; VOICE; VOMITING; WEIGHT REDUCTION; ANIMAL; DRUG ANTAGONISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; QUINAZOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67651242368     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.18     Document Type: Article

References (69)

1. Wedge SR, Kendrew J, Hennequin LF et al.: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65(10), 4389-4400 (2005).
2. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7(5), 359-371 (2006).
3. Meyer M, Clauss M, Lepple-Wienhues A et al.: A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18(2), 363-374 (1999).
4. Gille H, Kowalski J, Li B et al. Analysis of biological effects and signalling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 276, 3222-3230 (2001).
5. Matsumoto T, Claesson-Welsh L: VEGF receptor signal transduction. Sci. STKE 112, RE21 (2001).
6. Folkman J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
7. Heckman CA, Holopainen T, Wirzenius M et al.: The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 68(12), 4754-4762 (2008).
8. Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9(Suppl. 1), 2-10 (2004).
9. Holash J, Davis S, Papadopoulos N et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99(17), 11393-11398 (2002).
10. Boyer SJ: Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Curr. Top Med. Chem. 2(9), 973-1000 (2002).
11. Hurwitz H, Fehrenbacher L, Novotny W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 23, 2335-2342 (2004).
12. Giantonio BJ, Catalano PJ, Meropol NJ et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
13. Sandler A, Gray R, Perry MC et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 356(3), 318 (2007).
14. Saltz LB, Clarke S, Díaz-Rubio E et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26(12), 2013-2019 (2008).
15. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295 (2003).
16. Smith NR, James NH, Oakley I et al.: Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol. Cancer Ther. 6(8), 2198-2208 (2007).
17. Maris JM, Courtright J, Houghton PJ et al.: Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr. Blood Cancer 50(3), 581-587 (2008).
18. Grose R, Dickson C: Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 16(2), 179-186 (2005)
19. Hattori Y, Itoh H, Uchino S et al.: Immunohistochemical detection of K-sam protein in stomach cancer. Clin. Cancer Res. 2(8), 1373-1381 (1996).
20. Moffa AB, Tannheimer SL ethier SP: Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol. Cancer Res. 2(11), 643-652 (2004).
21. Gowardhan B, Douglas DA, Mathers ME et al.: Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br. J. Cancer 92(2), 320-327 (2005).
22. St Bernard R, Zheng L, Liu W et al.: Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146(3), 1145-1153 (2005).
23. Takeda M, Arao T, Yokote H et al.: AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin. Cancer Res. 13(10), 3051-3057 (2007).
24. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K: Lymphangiogenesis and cancer metastasis. Nat. Rev. Cancer 2(8), 573-583 (2002).
25. Verhoef C, de Wilt JH, Verheul HM: Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. Curr. Pharm. Des. 12(21), 2623-2630 (2006).
26. Llovet JM, Ricci S, Mazzaferro V et al.: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
27. Motzer RJ, Hutson TE, Tomczak P et al. sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
28. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52(23), 6702-6704 (1992).
29. Jain R: Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat. Rev. Cancer 8, 309-316 (2008).
30. Gomez-Rivera F, Santillan-Gomez AA, Younes MN et al.: The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin. Cancer Res. 13(15 Pt 1), 4519-4527 (2007).
31. Willett CG, Duda DG, Czito BG et al.: Targeted therapy in rectal cancer. Oncology 21(9), 1055-1065 (2007).
32. Bozec A, Gros FX, Penault-Llorca F et al.: Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur. J. Cancer 44(13), 1922-1930 (2008).
33. MacPherson IR, Cassidy J: Challenges in combinational oncology studies. Pharm. Med. 22, 85-97 (2008).
34. Williams KJ, Telfer BA, Shannon AM et al.: Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol. Cancer Ther. 6(2), 599-606 (2007).
35. Geng L, Donnelly E, McMahon G et al.: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61(6), 2413-2419 (2001).
36. Koukourakis MI, Giatromanolaki A, Thorpe PE et al.: Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 60(11), 3088-3095 (2000).
37. Cao C, Albert JM, Geng L et al.: Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res. 66(23), 11409-11415 (2006).
38. Bozec A, Formento P, Lassalle S, Lippens C, Hofman P, Milano G: Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br. J. Cancer 97(1), 65-72 (2007).
39. Drevs J, Siegert P, Medinger M et al.: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25(21), 2993-2995 (2007).
40. Manegold C, von Pawel J, Zatloukal P et al.: Randomised, double-blind multicentre Phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J. Clin. Oncol. (Meeting Abstracts). 25(Suppl. 18) (2007).
41. Laurie SA, Gauthier I, Arnold A et al.: Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 26(11), 1871-1878 (2008).
42. Goss G, Shepherd FA, Laurie S et al.: A Phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. Eur. J. Cancer 25, 7649 (2008).
43. Laurie SA, Arnold A, Shepherd FA et al.: National Cancer Institute of Canada Clinical Trials Group Study Br.24, A randomized placebo controlled Phase II trial of Cediranib (Ced) plus carboplatin¶clitaxel (C_P) in advanced non-small cell lung cancer of any histology: further analyses. J. Thoracic Oncology 3(11), S304 (2008).
44. Laurie SA, Arnold A, Shepherd FA et al.: Randomised double-blind Phase II trial of carboplatin + paclitaxel (C+P) with either daily oral cediranib, an inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, or placebo, in advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 19 (Suppl. 8), viii90 (2008).
45. Johnson DH, Fehrenbacher L, Novotny WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191 (2004).
46. Miller K, Wang M, Gralow J et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
47. Miller KD, Miller M, Mehrotra S et al.: A physiologic imaging pilot study of breast cancer treated with AZD2171. Clin. Cancer Res. 12(1), 281-288 (2006).
48. Mayer EL, Hamel S, Savoie J et al.: AZD2171 for refractory breast cancer: a Phase 2 trial. Breast Cancer Res. 106(Suppl. 1), S274 (2007).
49. Denduluri N, Tan AR, Walshe J et al.: A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer. Clin. Breast Cancer 6(5), 460-463 (2005).
50. Denduluri N, Berman AW, Vatas U et al.: Cardiotoxicity after doxorubicin and AZD2171, an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, in patients (pts) with breast cancer. J. Clin. Oncol. (Meeting Abstracts). 25(Suppl. 18), 554 (2007).
51. Ryden L, Jirstrom K, Bendahl PO et al.: Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J. Clin. Oncol. 23(21), 4695-4704 (2005).
52. Petit AM, Rak J, Hung MC et al.: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151(6), 1523-1530 (1997).
53. Epstein M, Ayala RE, Tchekmedyian N et al.: HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF). Breast Cancer Res. Treat 76(Suppl. 1), S143 (2002).
54. Ryan CJ, Stadler WM, Roth B et al.: Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest. New Drugs 25(5), 445-451 (2007).
55. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143(2), 401-409 (1993).
56. Bok RA, Halabi S, Fei DT et al.: Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 61(6), 2533-2536 (2001).
57. Karakunnel JJ, Gulley JL, Arlen PM et al.: Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC). J. Clin. Oncol. 26, ASCO annual meeting proceedings (2008) (Abstract 5136).
58. Sridhar SS, Mackenzie MJ, Hotte SJ et al.: Activity of cediranib (AZD2171) in patients with previously untreated metastatic renal cell cancer (RCC). A Phase II trial of the PMH Consortium. ASCO annual meeting proceedings. J. Clin. Oncol. 26 (2008) (Abstract 5047).
59. Cunningham D, Wong RP, D'haens G et al.: A Phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results. ASCO annual meeting proceedings. J. Clin. Oncol. 26 (2008) (Abstract 4028).
60. Matulonis UA, Berlin ST, Krasner CN et al.: Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. ASCO annual meeting proceedings. J. Clin. Oncol. 26 (2008)
61. Hirte HW, Vidal L, Fleming GF et al.: A Phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. ASCO annual meeting proceedings. J. Clin. Oncol. 26 (2008) (Abstract 5521).
62. Hormigo A, Gutin PH, Rafii S: Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer Cell 11(1), 6-8 (2007).
63. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83-95 (2007).
64. Gardner K, Leahy M, Alvarez-Gutierrez M, Judson I, Scurr M: Activity of the VEGFR/Kit tyrosine kinase inhibitor cediranib (AZD2171) in alveolar soft part sarcoma. Presented at: The 14th Annual Meeting of the Connective Tissue Oncology Society. London, UK, 15 November, 2008 (Abstract 34936).
65. Shields AF, Heath E, DeLuca P et al.: AZD2171 in combination with various anticancer regimens: Follow-up results of a Phase I multi-cohort study. ASCO annual meeting proceedings. J. Clin. Oncol. 25 (2007) (Abstract 3544).
66. Bradley DP, Tessier JL, Checkley D et al.: Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR Biomed. 21(1), 42-52 (2008).
67. Yang R, Thomas GR, Bunting S et al.: Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol. 27(6), 838-844 (1996).
68. Curwen JO, Musgrove HL, Kendrew J et al.: Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin. Cancer Res. 14(10), 3124-3131 (2008).
69. Langenberg M, van Herpen CM, De Bono JS et al.: Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized Phase II study of cediranib. ASCO annual meeting proceedings. J. Clin. Oncol. 26 (2008) (Abstract 3555).